|
||||
![]() Under the Limited Purpose Cooperative Research and Development Agreement, the two Department of Defense laboratories hope to formally begin testing whether Oxycyte, a perfluorocarbon therapeutic oxygen carrier that's designed to enhance oxygen delivery to damaged tissues, is safe and effective for therapy. If the results are positive, the agency will submit an application to the Food and Drug Administration for approval of Oxycyte in humans. Oxygen will provide information to the agencies for use in these tests but will retain ownership of the intellectual property, according to company Chairman and CEO Chris Stern. NEXT PAGE >> Related headlines UC Irvine banks $45 million for infectious disease research NIH: Masimo's SpCo may gauge asthma severity in kids May is Huntington's Disease Awareness month UC Irvine Medical Center lands stroke therapy center designation |
||||